The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up

Ravin J. Garg, Hagop Kantarjian, Susan O'Brien, Alfonso Quintás-Cardama, Stefan Faderl, Zeev Estrov, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

99 Scopus citations

Fingerprint

Dive into the research topics of 'The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds